Evidence map›Paper›PMID 28415817›Full record

SynthesisOncotarget2017

An updated meta-analysis of 23 case-control studies on the association between miR-34b/c polymorphism and cancer risk.

Hua Li, Shuling Diao, Jingsen Li, Baoxin Ma, Shuanghu Yuan

Abstract readMeta-AnalysisSystematic Review
In one paragraph

Synthesis in Oncotarget, 2017. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 4 papers, 2 of them syntheses that pooled it.

0numbers the graph read from it
0cells of the map it votes in
4citing papers in PubMed, 2 pooled it
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

4 citing papers in PubMed, 2 syntheses or guidelines pooled it.

  1. Pooled it
  2. Pooled it
  3. Article
  4. Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

5 authors.

Hua LiDepartment of Oncology, The Affiliated Hospital of Binzhou Medical University, Binzhou, Shandong 256603, China.
Shuling DiaoDepartment of Cardiology, The Affiliated Hospital of Binzhou Medical University, Binzhou, Shandong 256603, China.
Jingsen LiDepartment of Cardiology, The Affiliated Hospital of Binzhou Medical University, Binzhou, Shandong 256603, China.
Baoxin MaDepartment of Cardiology, The Affiliated Hospital of Binzhou Medical University, Binzhou, Shandong 256603, China.
Shuanghu YuanDepartment of Radiotherapy, Shandong Cancer Hospital and Institute, Jinan, Shandong 250117, China.

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

The association between in microRNA-34b/c gene rs4938723 polymorphisms and cancer risk remains inconclusive. This meta-analysis was performed to analyze the association between microRNA-34b/c rs4938723 polymorphism and risk for cancer development. In total, 304 studies from PubMed, Embase, Web of Science, Wanfang, and Chinese National Knowledge Infrastructure databases were examined, and 23 studies were included in this meta-analysis. The 23 selected studies involved 10,812 cancer cases and 11,719 controls. Odds ratios (ORs) and 95% confidence intervals (CIs) were calculated to measure the strength of the association. Our results indicate a significant association between the rs4938723 polymorphism and cancer risk in the overdominant model (P heterogeneity = 0.018, OR = 1.093, and 95% CI = 1.015-1.177 for CT vs. CC/TT). Using a stratified subgroup analysis, rs4938723 polymorphisms were associated with an increased risk for hepatocellular carcinoma, but decreased risk for colorectal, gastric, and esophageal squamous cell cancer. These findings indicate that the rs4938723 gene is a susceptible locus for cancer.

Indexed as

Genetic Predisposition to DiseaseGenotypeHumansMicroRNAsNeoplasmsOdds RatioPolymorphism, Single NucleotideRisk FactorsMicroRNAsMIRN34 microRNA, humancancer riskmeta-analysispolymorphismrs4938723systematic review

Identifiers

PMID28415817
PMCPMC5438700

What OpenQuestion holds

Textmetadata
LicenceCC BY
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.